{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.38","upperLimit":"103.66","value":"50.96"},{"groupId":"OG001","lowerLimit":"40.51","upperLimit":"81.32","value":"46.04"},{"groupId":"OG002","lowerLimit":"29.86","upperLimit":"103.74","value":"44.23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"The median (min, max) Half-Life of entinostat stratified by study part and dose level. The half-life (t1/2) was calculated using the equation t1/2 = 0.693/λz, where the terminal elimination rate constant (λz) was determined from a least-squares regression of the log-transformed plasma concentration vs. time data for the last 3 - 4 time points.","dispersionType":"Full Range","groups":[{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 3 mg/m2","id":"OG000","title":"Stratum 1 With 3 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 4 mg/m2","id":"OG001","title":"Stratum 1 With 4 mg/m²"},{"description":"Patients with recurrent or refractory solid tumors without bone marrow involvement, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at the RP2D (4 mg/m2)","id":"OG002","title":"PK Part With 4 mg/m²"}],"paramType":"MEDIAN","populationDescription":"All eligible enrolled patients.","reportingStatus":"POSTED","timeFrame":"Plasma concentrations were measured at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1.","title":"Half-life of Entinostat","type":"PRIMARY","unitOfMeasure":"Hours"}